<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04482062</url>
  </required_header>
  <id_info>
    <org_study_id>2020-05</org_study_id>
    <nct_id>NCT04482062</nct_id>
  </id_info>
  <brief_title>TRISCEND II Pivotal Trial</brief_title>
  <official_title>Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve
      replacement system
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center, randomized controlled pivotal clinical trial to
      evaluate the safety and effectiveness of the EVOQUE System with optimal medical therapy (OMT)
      compared to OMT alone in the treatment of patients with at least severe tricuspid
      regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and
      annually through 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TR Grade reduction and composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of number of participants with reduction in TR and composite endpoint event improvement between experimental and active comparator arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Major Adverse Events (MAE)</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of Major Adverse Events (MAE) in experimental arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention, heart failure hospitalizations, KCCQ improvement, NYHA functional class improvement, and 6-minute walk distance improvement</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of number of participants with composite endpoint events between experimental and active comparator arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint including reduction in TR grade, change in QOL from baseline, death and heart failure hospitalization, all-cause hospitalization, all-cause mortality, and change in right ventricular end diastolic volume index</measure>
    <time_frame>1 year</time_frame>
    <description>Hierarchical comparison of number of participants with composite endpoint events between experimental and active comparator arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">675</enrollment>
  <condition>Tricuspid Valve Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Tricuspid Valve Disease</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Edwards EVOQUE System &amp; OMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy (OMT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single-Arm Registry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation who are not eligible for randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards EVOQUE System</intervention_name>
    <description>Transcatheter tricuspid valve replacement with the Edwards EVOQUE System in conjunction with OMT</description>
    <arm_group_label>Edwards EVOQUE System &amp; OMT</arm_group_label>
    <arm_group_label>Single-Arm Registry</arm_group_label>
    <other_name>Transcatheter tricuspid valve replacement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical Therapy</intervention_name>
    <description>Optimal Medical Therapy</description>
    <arm_group_label>Optimal Medical Therapy (OMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic tricuspid regurgitation (TR) despite medical therapy

          -  TR graded as severe or greater

          -  Appropriate for transcatheter tricuspid valve replacement per the local heart team

        Exclusion Criteria:

          -  Tricuspid valve anatomic contraindications

          -  Need for emergent or urgent surgery or any planned cardiac surgery within the next 12
             months

          -  Hemodynamic instability

          -  Refractory heart failure requiring advanced intervention

          -  Currently participating in another investigational study in which the patient has not
             reached a primary endpoint
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Gammie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Hahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susheel Kodali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TMTT Clinical</last_name>
    <phone>949-250-2500</phone>
    <email>TMTT_Clinical@Edwards.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

